Alice is the CEO of Verge Genomics, which she co-founded in 2015 as a next-generation drug discovery company using human genomic data to defeat neurodegeneration. Alice has been at the forefront of systems biology research for over seven years at the National Cancer Institute, the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and UCLA. She graduated from Princeton University magna cum laude with high honors in Molecular Biology and subsequently trained for five years in the UCLA-Caltech MD/Ph.D. program investigating gene networks involved in neuro-regeneration. Alice has received numerous awards for her work as a scientist and entrepreneur, including the prestigious Paul & Daisy Soros Fellowship for New Americans and Forbes' 30 under 30 in Science.